Ifosfamide, carboplatin and etoposide in recurrent malignant glioma

Oncology

Volumn 80, Issue 5-6, 2011, Pages 330-332

  Schafer N ^a   Tichy, J ^c   Thanendrarajan, S ^a   Kim, Y ^a   Stuplich, M ^a   Mack, F ^a   Rieger, J ^c   Simon, M ^a   Scheffler, B ^a   Bostrom J ^a,b   Steinbach, J P ^c   Herrlinger, U ^a   Glas, M ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b MediClin Robert Janker Clinic   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Carboplatin; Etoposide; Ifosfamide; Recurrent glioblastoma

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; DASATINIB; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; NIMUSTINE; TEMOZOLOMIDE; TENIPOSIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRAIN DISEASE; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TREATMENT FAILURE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; CARBOPLATIN; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; GLIOMA; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 79960679011     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000330358     Document Type: Article

References (8)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996. (Pubitemid 40349501)
2. Glas M, Hundsberger T, Stuplich M, Wiewrodt D, Kurzwelly D, Nguyen-Huu B, Rasch K, Herrlinger U: Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma. Oncology 2009; 76: 184-189.
3. Happold C, Roth P, Wick W, Steinbach JP, Linnebank M, Weller M, Eisele G: ACNUbased chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol 2009; 92: 45-48.
4. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA: Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010; 28: 1168-1174.
5. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740.
6. Sanson M, Ameri A, Monjour A, Sahmoud T, Ronchin P, Poisson M, Delattre JY: Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: A phase II study. Eur J Cancer 1996; 32: 2229-2235.
7. Aoki T, Mizutani T, Nojima K, Takagi T, Okumura R, Yuba Y, Ueba T, Takahashi JA, Miyatake S, Nozaki K, Taki W, Matsutani M: Phase II study of ifosfamide, carboplatin, and etoposide in patients with first recurrence of glioblastoma multiforme. J Neurosurg 2010; 112: 50-56.
8. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM: Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963-1972.